describ
case
estim
incid
extract
hospit
record
relat
zygomycosi
metropolitan
franc
includ
mainland
franc
island
corsica
french
hospit
inform
system
programm
de
du
inform
pmsi
manageri
tool
base
systemat
collect
standard
administr
medic
inform
new
hospit
admiss
estim
public
privat
hospit
use
tool
includ
thirdlevel
structur
ie
univers
hospit
refer
hospit
anonym
extract
dataset
limit
sociodemograph
inform
age
sex
resid
area
made
avail
specif
epidemiolog
studi
medic
inform
includ
main
caus
admiss
princip
diagnosi
relat
medic
condit
entri
variou
associ
diagnos
durat
stay
mode
admiss
discharg
major
medic
activ
perform
stay
diseas
code
accord
intern
classif
diseas
revis
code
system
stabl
studi
period
convers
code
medic
surgic
procedur
determin
nation
level
evolv
time
notabl
chang
occur
estim
overal
cfr
death
occur
hospit
includ
among
readmit
patient
identifi
pmsi
take
account
death
occur
discharg
also
use
data
death
certif
avail
institut
charg
record
analyz
death
certif
cepidc
certif
complet
time
death
attend
physician
hospit
home
record
main
caus
death
ie
direct
immedi
caus
well
underli
diseas
may
contribut
death
certif
sent
cepidc
code
accord
use
pmsi
record
code
identifi
correspond
clinic
present
zygomycosi
mucormycosi
distinguish
first
admiss
rehospit
creat
uniqu
patient
identifi
chain
variabl
year
birth
deriv
patient
age
date
admiss
gender
resid
postal
code
identifi
use
match
pmsi
cepidc
data
identifi
addit
death
check
duplic
howev
cepidc
identifi
base
exact
year
birth
pmsi
deriv
year
birth
age
admiss
defin
uniqu
case
identifi
detect
time
pmsi
period
case
detect
time
classifi
new
case
first
occurr
databas
subsequ
one
code
readmiss
check
duplic
analyz
uniqu
new
case
incid
zygomycosi
case
classifi
accord
clinic
present
avail
sever
bodi
local
report
select
sever
one
either
singl
stay
subsequ
admiss
instanc
associ
unspecifi
local
gastrointestin
cutan
local
togeth
pulmonari
rhinocerebr
dissemin
local
classifi
latter
categori
similarli
analyz
underli
diseas
potenti
associ
zygomycosi
focus
known
risk
factor
combin
code
medic
procedur
condit
bone
marrow
transplant
code
procedur
diseas
take
consider
patient
underli
condit
introduc
hierarchi
first
creat
bone
marrow
transplant
bmt
categori
includ
autolog
allogen
bmt
without
graft
versu
host
diseas
reduc
underreport
bia
look
bmt
occurr
incid
readmit
patient
chang
code
system
regard
medic
procedur
identif
autolog
versu
allogen
bmt
possibl
second
categori
label
hematolog
malign
includ
neutropenia
aplast
anemia
acut
lymphoid
myeloid
leukemia
lymphoma
disord
myeloid
system
third
categori
label
nonhematolog
immunodepress
includ
solid
organ
cancer
hiv
infect
solid
organ
transplant
andor
reject
transplant
convent
bmt
patient
without
graft
versu
host
diseas
also
neutropenia
classifi
bmt
categori
final
analyz
diabet
type
patient
separ
categori
patient
immunosuppress
condit
diabet
immunosuppress
condit
kept
main
risk
factor
take
account
popul
growth
use
nation
popul
censu
estim
annual
incid
rate
enabl
trend
comparison
use
approach
specif
incid
rate
patient
underli
factor
zygomycosi
patient
present
underli
factor
numer
total
popul
denomin
heterogen
age
distribut
popul
accord
geograph
area
standard
incid
rate
gender
age
group
perform
district
depart
metropolitan
franc
popul
district
rang
million
inhabit
cfr
consid
possibl
underreport
pmsi
combin
inaccuraci
registr
caus
death
cepidc
estim
number
death
could
miss
data
sourc
perform
analysi
follow
method
synthes
gallay
et
al
tabl
number
death
identifi
one
respect
databas
subscript
indic
identifi
indic
identifi
databas
enter
respect
tabl
box
hypothesi
sourc
independ
death
could
miss
sourc
estim
equat
total
number
death
n
varianc
confid
interv
ci
var
n
ci
n
n
respect
cfr
estim
impair
unavail
accur
inform
underli
medic
condit
death
identifi
cepidc
addit
approxim
year
birth
use
pmsi
dataset
limit
cfr
studi
age
group
therefor
restrict
analysi
overal
cfr
underli
diseas
whenev
possibl
made
assumpt
miss
data
statist
analysi
perform
use
excel
microsoft
corpor
redmond
wa
usa
statacorp
lp
colleg
station
tx
usa
softwar
fisher
exact
test
use
appropri
compar
group
trend
assess
use
poisson
regress
appropri
present
result
ci
p
valu
consid
p
signific
hospit
stay
link
zygomycosi
incid
case
identifi
public
privat
hospit
metropolitan
franc
male
femal
sex
ratio
mean
age
year
median
year
rang
year
annual
incid
rate
air
increas
casesmillion
person
person
figur
yearli
increas
p
averag
year
studi
air
person
ci
averag
air
increas
age
children
age
year
patient
year
age
figur
number
patient
per
district
resid
vari
period
averag
standard
incid
rate
vari
person
per
district
per
year
highest
rate
observ
rural
district
host
inhabit
p
ci
ci
versu
nationwid
greater
pari
area
host
million
inhabit
district
averag
standard
incid
rate
per
year
ci
significantli
differ
rate
nation
underli
diseas
among
zygomycosi
casepati
compris
patient
immunosuppress
condit
patient
bmt
patient
hematolog
malign
patient
nonhematolog
immunodepress
tabl
patient
diabet
also
experienc
underli
immunosuppress
condit
classifi
zygomycosi
patient
hematolog
malign
specif
air
increas
time
casesmillion
person
year
p
figur
also
increas
patient
bmt
year
p
diabet
year
p
incid
significantli
alter
time
patient
nonhematolog
immunodepress
patient
known
risk
factor
data
shown
report
present
includ
pulmonari
rhinocerebr
cutan
dissemin
local
digest
tract
mention
uniqu
local
patient
inform
avail
patient
sixtyon
death
record
pmsi
dataset
includ
death
report
among
readmit
patient
identifi
addit
death
cepidc
result
total
death
studi
period
overal
cfr
ci
lethal
evolv
time
increas
onward
averag
cfr
period
versu
period
p
use
method
overal
expect
number
death
would
reach
ci
cfr
ci
specif
cfr
accord
underli
condit
calcul
death
report
pmsi
inform
avail
tabl
greater
patient
hematolog
malign
bmt
patient
nonhematolog
immunodepress
diabet
known
risk
factor
cfr
respect
retrospect
analysi
hospit
record
provid
populationbas
estim
zygomycosi
incid
trend
period
nation
level
show
increas
incid
popul
p
averag
annual
incid
rate
franc
lower
incid
report
populationbas
studi
ree
et
al
california
howev
result
base
passiv
routin
system
wherea
activ
laboratorybas
surveil
implement
san
francisco
bay
area
time
high
hiv
preval
system
smaller
sampl
size
million
san
francisco
vs
million
franc
survey
perform
spain
incid
repres
sampl
particip
hospit
cover
one
third
countri
popul
ie
million
inhabit
compar
data
french
mycosi
studi
group
recent
establish
voluntari
network
french
mycologist
coordin
nation
refer
center
mycos
antifung
nrcma
network
cover
univers
tertiari
level
hospit
franc
report
averag
case
per
year
sinc
versu
studi
period
differ
could
sever
nonexclus
reason
first
diagnos
zygomycosi
easi
recent
underlin
cultur
posit
zygomycet
alway
mean
infect
mani
gastrointestin
case
report
pmsi
may
falseposit
case
result
laboratori
contamin
unusu
distribut
clinic
present
found
studi
fact
one
third
clinic
inform
miss
favor
hypothesi
second
may
overestim
number
case
undetect
duplic
code
error
howev
invers
underreport
voluntarybas
nrcma
network
may
also
occur
relev
hospit
discharg
data
base
code
estim
incid
rare
diseas
regularli
debat
limit
diagnosi
accuraci
inconsist
diseas
code
undetect
duplic
anonym
data
record
report
chang
et
al
compar
administr
data
medic
record
unit
state
posit
predict
valu
code
detect
invas
aspergillosi
low
author
stress
code
may
sometim
assign
final
diagnosi
confirm
may
assign
clinician
charg
patient
consider
also
true
pmsi
overreport
estim
cancer
thyroid
studi
base
district
mesothelioma
invers
underreport
caus
diagnost
code
error
estim
hafdinejjari
et
al
et
al
respect
nevertheless
administr
data
use
tool
estim
trend
sever
infect
like
zygomycosi
sinc
patient
like
hospit
especi
tertiari
care
center
particip
pmsi
abl
document
incid
zygomycosi
increas
popul
patient
hematolog
malign
bmt
alreadi
notic
popul
increas
number
record
case
could
link
frequent
prescript
antifung
drug
lack
activ
zygomycet
voriconazol
caspofungin
howev
role
previou
exposur
antifung
drug
appear
exclus
incid
also
increas
popul
patient
diabet
mellitu
popul
known
commonli
expos
longterm
antifung
therapi
increas
number
popul
risk
increas
incid
prolong
surviv
time
could
explain
increas
observ
studi
per
year
patient
hematolog
malign
bmt
patient
respect
howev
data
nation
agenc
charg
surveil
transplant
indic
number
hematopoiet
stem
cell
transplant
increas
per
year
p
similarli
document
per
year
increas
zygomycosi
patient
diabet
parallel
diabet
preval
increas
estim
year
franc
thu
tend
consid
observ
trend
reflect
genuin
increas
zygomycosi
case
atrisk
popul
pmsi
provid
scarc
inform
sociodemograph
characterist
patient
review
case
publish
roden
et
al
indic
f
sex
ratio
averag
age
year
versu
f
sex
ratio
year
studi
respect
howev
age
distribut
underli
condit
like
differ
place
evolv
time
thu
allow
strict
comparison
anoth
limit
pmsi
absenc
inform
regard
circumst
exposur
portal
entri
highest
incid
rate
found
rural
district
other
compar
age
gender
distribut
may
indic
particular
exposur
mold
rural
environ
instanc
profession
exposur
increas
awar
diseas
among
clinician
microbiologistsmycologist
correspond
region
report
bias
may
also
partial
explain
overal
low
casefat
ratio
studi
highest
estim
versu
roden
review
case
nevertheless
cfr
patient
sever
immunosuppress
condit
tabl
close
valu
report
literatur
cfr
studi
populationbas
report
literatur
mostli
refer
larg
rel
old
seri
seri
immunocompromis
patient
sever
underli
diseas
whose
outcom
expect
wors
nonimmunocompromis
gener
popul
also
cfr
studi
may
includ
longterm
outcom
discret
time
frame
exampl
year
surviv
rate
inform
avail
type
studi
death
occur
hospit
systemat
report
pmsi
occur
outsid
hospit
may
underdiagnos
cepidc
mani
practition
awar
zygomycosi
falseposit
case
instanc
zygomycet
cultur
without
infect
also
influenc
cfr
calcul
increas
denomin
wide
rang
cfr
estim
calcul
method
reflect
uncertainti
recent
progress
earli
diagnosi
treatment
strategi
time
also
consid
instanc
cfr
rhinocerebr
form
may
vari
roden
et
al
show
decreas
global
cfr
time
sinc
antifung
drug
combin
surgic
resect
play
import
role
decreas
lethal
local
infect
cfr
reportedli
decreas
patient
treat
antifung
drug
alon
patient
receiv
combin
antifung
drug
surgic
treatment
given
stabl
increas
incid
year
especi
among
patient
present
known
risk
factor
figur
tend
consid
increas
number
zygomycosi
case
like
reflect
actual
tempor
trend
zygomycosi
infect
diagnos
french
public
privat
hospit
despit
limit
link
sourc
data
use
studi
provid
use
overview
zygomycosi
incid
trend
decad
western
european
countri
level
stress
grow
frequenc
sever
infect
need
increas
awar
among
clinician
earli
diagnosi
treatment
especi
patient
hematolog
malign
bmt
andor
diabet
state
chang
et
al
administr
data
regard
use
screen
tool
complet
medic
record
investig
fact
studi
repres
opportun
launch
retrospect
studi
zygomycosi
case
identifi
pmsi
nrcma
studi
provid
descript
zygomycosi
case
outcom
franc
addit
enabl
us
evalu
predict
valu
administr
data
rare
diseas
